CTLA4 and neoplasm: In the clinical trial patients, high PD-L1 expression on pretreatment tumor biopsies was associated with persistent T cell exhaustion and disease progression after combination treatment, suggesting that combination therapy targeting both PD-L1 and CTLA-4 may be important for the optimization of this immunotherapy approach [22, 42].